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A plaque-reduction assay was used to examine the susceptibility of five
phosphonoformic acid-resistant variants of herpes simplex virus type 1 to
arabinosylnucleosides and aphidicolin. These viruses were cross-resistant to
arabinosylhypoxanthine and to arabinosyladenine when tested in the absence of
deoxycoformycin, a deaminase inhibitor. In the presence of deoxycoformycin, no
cross-resistance between arabinosyladenine and phosphonoformic acid was ob-
served. The two variants tested were cross-resistant to arabinosylthymine, and all
five variants were collaterally susceptible to aphidicolin inhibition.
In recent years, several anti-herpes simplex
virus (HSV) agents have been discovered which
depend on HSV-specified enzymes for activity.
They can be divided into two general categories:
those metabolized by HSV deoxythymidine ki-
nase (HSV-TK) and those which are not (4). The
activity of many of these agents can be changed
through alterations in the biochemical properties
of virus enzymes, and variants with different
drug susceptibilities have been isolated and
characterized by many laboratories (5-7, 10-
15). A recent study claimed that mutation in the
HSV DNA polymerase gene conferred marked
resistance to arabinosyladenine (araA) (6),
whereas other investigators have reported diffi-
culty in isolating variants highly resistant to this
agent (14, 21). Several of the araA-resistant
variants described were cross-resistant to anoth-
er anti-HSV agent, phosphonoacetic acid, which
also exerts its action on HSV DNA polymerase
(9, 13). Studies which describe araA-resistant
HSV variants have not included an adenosine
deaminase inhibitor (6, 19) which could prevent
the conversion of araA to arabinosylhypoxan-
thine (araHx), a less active antivirus compound
(16, 20, 22). Therefore, it is conceivable that the
araA resistance observed by others could actual-
ly reflect decreased susceptibility of HSV to
araHx. This communication describes a reex-
amination of araA resistance, using a group of
five variants which were independently selected
in 1 mM phosphonoformic acid (PFA), a conge-
ner of phosphonoacetic acid. The mechanism of
PFA resistance is the induction of altered HSV
DNA polymerase in cells infected with these
viruses (8). Also, we report a preliminary study
with aphidicolin, an agent which is a specific
inhibitor of replicative DNA polymerase, includ-
ing HSV DNA polymerase (2, 18). Since the
HSV variants used in this study induce altered
DNA polymerase, we examined these viruses
for altered susceptibility to aphidicolin.
MATERIALS AND METHODS
Drug susceptibility was tested by a plaque-reduction
assay. Confluent monolayers of Vero cells in 7-cm2
plastic wells (Linbro) were inoculated with 150 or
1,500 PFU of virus in 0.2 ml of RPMI 1640 medium
supplemented with 1% calf serum (GIBCO Labora-
tories). After 30 min of adsorption at 37°C, the inocu-
lum was replaced with 1 ml of medium supplemented
with carboxymethylcellulose to 1% and drugs at vari-
ous concentrations. Each treatment was done in dupli-
cate. The cells were fixed and stained after 2 days with
0.8% crystal violet in 50%o ethanol, and the wells were
examined microscopically for plaques. Determinations
of drug susceptibility were repeated at least twice on
separate occasions, and reproducible results were
obtained. Stock solutions of drugs were dissolved in
water, filter sterilized, and stored at -20°C, except for
aphidicolin, which was made 30 mM in dimethyl
sulfoxide.
RESULTS AND DISCUSSION
The dose responses of variants PFAr-1 to
PFAr-5 and a fresh plaque-purified isolate of the
parent strain (KOS) tested for inhibition by araA
and an adenosine deaminase inhibitor, deoxyco-
formycin (dCF), by araA alone, and by araHx
are shown in Fig. 1A, B, and C, respectively.
The concentration of dCF used (3.5 ,uM) had no
antiviral activity. A comparison among drugs for
activity against the KOS strain shows that
araHx was less potent than araA when tested
alone (Fig. 1C compared with Fig. 1B) or in
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FIG. 1. Susceptibilities of viruses to arabinosylnu-
cleotides, using a plaque-reduction assay. Inhibition of
plaque formation by araA and 3.5 ,uM dCF (A), araA
alone (B), araHx (C), and araT (D). Results are
expressed as plaque number in the presence of drug
given as a percentage of plaques in control, untreated
cultures. Symbols: 0, KOS; -, PFAT-1;
PFAr-2; A, PFAr-3; U------, PFAr-4;
*------0, PFAT-5. For clarity, the data in (A) shows
only the result for the parent virus and for PFAr-1;
however, the other variants had the same susceptibil-
ity to araA. When araA was tested alone (B), PFAr-4
was indistinguishable from PFAr-2. For araHx (C),
PFAr-1 and PFAr-4 were indistinguishable from PFAr-
2.
combination with dCF (Fig. 1C compared with
Fig. 1A). dCF increased the potency of araA
(Fig. 1A compared with Fig. 1B), suggesting that
cellular adenosine deaminase played an impor-
tant role in determining the activity of araA.
These results are consistent with previous re-
ports (16, 20, 22). A comparison among viruses
for each drug shows that all viruses were equally
susceptible to araA tested in the presence of
dCF (Fig. 1A). However, the variants were less
susceptible to araA alone since plaque formation
by these viruses was unaffected by 55 ,uM araA,
which was the 50%o effective dose for KOS (Fig.
1B). A similar result was obtained with araHx
(Fig. IC). In this case, the degree of resistance
did not appear as marked, but this could partly
reflect a limitation of the plaque-reduction assay
which has been discussed elsewhere (19), since
the higher concentrations of araHx used were
close to levels which made the scoring of
plaques difficult after 2 days of incubation. The
results from a yield-reduction assay confirmed
that variants were resistant to araHx because
growth of these viruses at 18 h postinfection was
unaffected by 160 ,uM araHx, which was the
50% effective dose for KOS. The simplest inter-
pretation of these results is that PFA resistance
confers decreased susceptibility to araHx, but
the data in Fig. 1B and C are not consistent with
this proposal, since araA without dCF was much
more active against the variants than araHx.
This discrepancy could be explained if there was
some interaction between the metabolites of
araA and araHx on biochemical targets. HSV
DNA polymerase may be involved because the
arabinosylnucleotide triphosphates, araATP and
araHxTP, are known to compete with different
deoxynucleotide triphosphates for DNA polym-
erization (8, 9). Other biochemical targets could
also be involved since HSV DNA polymerase is
probably not the sole determinant of the antivi-
ral action of araA (10; this communication).
Two of the variants (PFAr-3 and PFAr-4) were
tested for susceptibility to arabinosylthymine
(araT), and both were found to be less suscepti-
ble than KOS (Fig. 1D). HSV-TK is one deter-
minant of araT sensitivity (1); however, both
PFAr-3 and PFAr-4 induced activities of HSV-
TK similar to those found in the KOS-infected
cells (data not shown). This suggests that differ-
ences in the activity of HSV-TK were not re-
sponsible for the araT resistance we observed.
Another determinant of araT sensitivity is HSV
DNA polymerase (1), and it has also been sug-
gested that susceptibility of HSV to araA corre-
TABLE 1. Sensitivity of purified HSV DNA polymerase to arabinosylnucleotide triphosphates in synthetic
reactions
Analog Competing Ki (>M) of HSV DNA polymerase from:'substrate KOS PFAr-1 PFAr-2 PFAr-3 PFAr-4 PFAr_5
araATP dATP 0.29 0.78 1.50 1.60 1.30 0.48
araHxTP dGTP 2.6 22 31 28 28 12
araTTP dTTP 0.14 0.52 1.14 1.10 1.01 0.24
a Competitive inhibition analysis and the determination of apparent Ki values have been described previously
(8). The apparent K,'s for araHxTP were given in the same report and are included here for comparison.
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FIG. 2. Susceptibilities of viruses to aphidicolin,
using a plaque-reduction assay. Results are expressed
as plaque number in the presence of drug given as a
percentage of plaques in control untreated cultures.
Symbols: 0, KOS; *-d, PFAr-1; PFAr
2; A, PFAr-3; U------, PFAr-4; 0------0, PFAr-5.
lated with the sensitivity of HSV DNA polymer-
ase to araATP inhibition in vitro (6, 9).
Therefore, the triphosphate derivatives of araA,
araHx, and araT were tested against purified
variant DNA polymerases to see if the biological
and kinetic data were in agreement (Table 1).
araATP, araHxTP, and araTTP all inhibited the
incorporation of their competing substrates into
DNA, but these triphosphates were less potent
inhibitors of variant enzymes than the parent
DNA polymerase. These results show that the
changes in HSV DNA polymerase which were
associated with PFA resistance (8) had also
altered the binding behavior of arabinosylnu-
cleotides, despite their base moiety. Further-
more, a general correlation between the kinetic
and biological data did apply to araHx and araT,
but not to araA. Kinetic alterations in HSV
DNA polymerase which lower its affinity for
araATP without affecting susceptibilities of vari-
ants to araA in culture have also been reported
by others (10). These observations suggest that
biochemical determinants other than the HSV
DNA polymerase may be important for the
antiviral action of araA. The data presented
support the conclusion that the araA resistance
described previously (6, 19) was probably due to
omission of an adenosine deaminase inhibitor
from experiments. However, our results clearly
do not rule out kinetic alterations in HSV DNA
polymerase as a mechanism for araA resistance
in some cases. One possibility is that mutagene-
sis could increase the probability of such vari-
ants arising in a viral population.
A close examination of the apparent Ki values
given in Table 1 and the biological data in Fig. 1
reveals a poor correlation between these results
for some variants. The DNA polymerases in-
duced by PFAr-1 and PFAr-5 had the highest
affinity for araATP and araHxTP of the variant
enzymes examined, but these two viruses were
the least susceptible to araA and araHx in cul-
ture (Fig. 1B and C). This observation could be
explained if these variants were capable of alter-
ing concentrations of adenosine deaminase in
infected cells. There is a report which demon-
strated that one strain of HSV had no effect on
the levels of this enzyme in HeLa cells (3);
however, this possibility has not been excluded
for the variants described here.
Aphidicolin inhibition of virus plaque forma-
tion is shown in Fig. 2. The variants were more
susceptible than KOS. Catalysis by DNA poly-
merases purified from variant-infected cells was
also more sensitive to inhibition by aphidicolin
than control reactions catalyzed by the parent
enzyme (unpublished observation). The detailed
information will be published elsewhere. Aphidi-
colin inhibition was not selective for the parent
virus since the 50% inhibitory dose (0.3 jxM) for
Vero cell growth was similar to that concentra-
tion which reduced the yield of KOS by 50%o (0.4
,uM). In contrast, aphidicolin at 0.05 ,uM inhibit-
ed the yield of PFAr-1 and PFAr-2 by 50% and
had a nominal effect on cell growth, which
suggests that the drug may be acting selectively
on these variants. These results could have
some implication for antiviral chemotherapy,
but it is not yet known whether polymerase
variants will present a problem for effective
treatment of disease associated with HSV infec-
tion. However, a recent study showed that vari-
ants resistant to 9-[2-hydroxyethoxy)meth-
yl]guanine (acyclovir) were present in popula-
tions from clinical isolates and that some viruses
possibly induced altered HSV DNA polymerase
(17). The viruses used in this study behaved as
other variants selected in PFA or phosphono-
acetic acid (5, 10, 13, 15), and all five were cross-
resistant to acyclovir (50% effective dose from
plaque-reduction assay: KOS, 1.5 ,uM; PFAr-l,
22 ,uM; PFAr-2, 23 ,uM; PFAr-3, 26 FLM; PFAr-4,
22 ,uM; PFAr-5, 32 ,uM). If the increased suscep-
tibility to aphidicolin is always associated with
kinetic alterations in HSV DNA polymerase,
then the use of aphidicolin in combination che-
motherapy could be considered for treatment of
HSV infections.
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